Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More
Utilization Challenges Hold Back the Adoption of Bispecific Therapies
February 23rd 2024Bispecific antibodies are a powerful class of therapy that offer an alternative or complement to CAR T-cell therapies, but there are similar challenges to implementing them in clinical practice. In live events, experts discussed their experience setting up standard operating procedures in their cancer centers.
Read More
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
February 16th 2024In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More